BDTX — Black Diamond Therapeutics Share News
0.000.00%
Last trade - 00:00- $100.28m
- -$17.98m
- $70.00m
U.S. STOCKS ON THE MOVE-Spirit AeroSystems, Boeing, Roblox
U.S. STOCKS ON THE MOVE-Microsoft, Wyndham Hotels & Resorts, Daktronics
NASDAQ RESUMED AT 09:43 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:33 AM
U.S. STOCKS ON THE MOVE-Wendy's, Bristol Myers Squibb, Macy's
Brief: Black Diamond Therapeutics Announces Preliminary Phase 2 Data For Silevertinib In 1L Nsclc
Black Diamond rises as lung cancer drug meets main goal
U.S. RESEARCH ROUNDUP- Autodesk, Crowdstrike, Zscaler
Black Diamond narrows Q3 net loss as R&D costs drop
Black Diamond Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Black Diamond Therapeutics Q2 EPS $-0.19
Black Diamond Therapeutics Q2 net loss narrows as costs drop
Black Diamond Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview
Black Diamond Therapeutics Inc expected to post earnings of 20 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Gilead Sciences, Plug Power, BGM Group
U.S. STOCKS ON THE MOVE-Gilead Sciences, Plug Power, BGM Group
U.S. STOCKS ON THE MOVE-Aterian, Autodesk, Ollie's
Black Diamond rises on licensing deal for tumor treatment
Brief: Servier And Black Diamond Therapeutics Announce Global Licensing Agreement For BDTX-4933, A Targeted Oncology Therapy